Tuesday, September 21, 2010
Effects of glycemic load on metabolic risk markers... [Am J Clin Nutr. 2010] - PubMed result
Friday, February 5, 2010
Published article: The heart and cardiovascular system in the Qur'an and Hadeeth
(http://www.elsevier.com/wps/
In this paper it has been clearly mentioned:
"The Islamic empire, for more than 1000 years, remained the most advanced and civilized empire in the world, and the inspiration of all the scientific and medical discoveries and practices stemmed from the teachings of the Qur'an and the Hadeeth, teachings that strongly encouraged and supported the drive to seek knowledge and to make scientific achievements and discoveries."
Thursday, November 26, 2009
Atherosclerosis in Mummies 3500 Years Old: need to look beyond traditional risk factors.
Method of Fish Preparation Affects Cardiac Benefits
Although the amount of fish consumed was key--along with whether it was high in omega-3 fatty acids, as is wild salmon and tuna--the results also indicate an important role for the method of cooking.
Those consuming adequate amounts of baked or boiled fish had lower rates of coronary heart disease (CHD) mortality during follow-up than those eating little fish. But those eating deep fried fish every day actually had higher mortality, as did those consuming salted or dried fish, she noted. The only method of frying fish that seemed protective was stir-frying, used primarily by the Japanese.
"Our findings suggest the method of preparation of fish may modify the protective effect of omega-3 fatty acids. The results can help educate people on how much fish to eat and how to cook it to prevent heart disease," Meng said. "If you want to eat fried fish, do it occasionally, but try to avoid it. Or eat it the Japanese way and stir fry it."
23% Reduction in Heart Disease Among Men Who Ate the Most Fish
Meng said that CHD mortality is known to differ by ethnicity in Hawaii, and that the disparities are not fully accounted for by known risk factors. She and her colleagues examined the source, type, amount, and frequency of dietary omega-3 consumption among participants in the Multiethnic Cohort (MEC) Study living in Los Angeles, CA and Hawaii. The cohort consisted of more than 80 000 men and 100 000 women of African American, Caucasian, Japanese, Native Hawaiian, and Latino descent, aged 45-75 years at recruitment, which occurred from 1993 to 1996; those with a history of myocardial infarction or angina were excluded. Food frequency questionnaires were used to examine fish consumption and omega-3 intake from other sources, such as plant materials like soy sauce.
The fact that the different ethnic groups in the MEC study have different sources of omega-3 provides a unique opportunity to look at this issue, and also to examine ethnic-specific data on methods of fish preparation, she said.
During an average of almost 12 years of follow-up, there were 2604 male and 1912 female deaths due to CHD.
Among men, those in the highest quintile (consuming a median of 3.3 g of dietary omega-3 fatty acids per day) had a 23% lower CHD mortality than those in the lowest quintile (median, 0.8 g per day), Meng said.
The benefits of omega-3 were more apparent in white, Japanese, and Latino men than in African Americans and native Hawaiians, she noted.
12%-15% Increase in CHD Death With Deep Fried, Salted, and Dried Fish
But these benefits were confined to raw fish or fish prepared by boiling or baking, she noted. Among both men and women, consumption of more than 6.2 g of deep fried fish per day (excluding stir-fried fish) led to a 12% increase in CHD mortality, Meng stressed, and even smaller amounts of salted or dried fish daily upped mortality by 15%. This latter effect could be due to the amount of sodium found in fish prepared in this way, she said.
Among men, Japanese ate the most fried fish, but they tended to prepare it by stir-frying, which does not seem to have the same risk as deep frying, Meng said. Second in consumption of fried fish were native Hawaiians, who also ate the most salted and dried fish, followed by African Americans.
Among women in general, the relation between fish consumption and mortality was "all in a protective direction," Meng said, but there was not as strong a dose-response as for men. Plant sources of omega-3, such as soy sauce and tofu, were particularly protective for women, she said, stressing that low-sodium products are best.
Source: http://www.medscape.com/viewarticle/713037
Thursday, November 5, 2009
Mediterranean Diet Delays the Need for Drug Therapy in Type 2 Diabetes
Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Trial
Ann Intern Med. 2009;151:306-314
Study Summary
Friday, October 30, 2009
LDL cholesterol levels
Thursday, April 16, 2009
Low Sodium Cooking
Appetizers
Meat and Main Dishes
Breakfast
Side Dishes and Salads
Sauces, Marinades and Dressings
Condiments, Spice Mixes and Mixes
Breads
Desserts, Snacks and Sweets
you can access the site at http://www.lowsodiumcooking.com/free/Archive.htm
Sunday, April 5, 2009
Adverse metabolic and cardiovascular consequences of not maintaining circadian rythm
In a recent study, Ciprian and colleagues found increased pathological remodeling and vascular injury in mice with aberrant circadian rhythms, Bmal1-knockout and Clock mutant. In addition, naive aortas from Bmal1-knockout and Clock mutant mice exhibit endothelial dysfunction. Akt and subsequent nitric oxide signaling, a pathway critical to vascular function, was significantly attenuated in arteries from Bmal1-knockout mice. The authors concluded that their data reveal a new role for the circadian clock during chronic vascular responses that may be of significance in the progression of vascular disease.
In another study by Scheer et at, Ten adults (5 female) underwent a 10-day laboratory protocol, wherein subjects ate and slept at all phases of the circadian cycle—achieved by scheduling a recurring 28-h “day.” Subjects ate 4 isocaloric meals each 28-h “day.” For 8 days, plasma leptin, insulin, glucose, and cortisol were measured hourly, urinary catecholamines 2 hourly (totaling ≈1,000 assays/subject), and blood pressure, heart rate, cardiac vagal modulation, oxygen consumption, respiratory exchange ratio, and polysomnographic sleep daily. Core body temperature was recorded continuously for 10 days to assess circadian phase. Circadian misalignment, when subjects ate and slept ≈12 h out of phase from their habitual times, systematically decreased leptin (−17%, P <>P <>P = 0.006), completely reversed the daily cortisol rhythm (P <>P = 0.001), and reduced sleep efficiency (−20%, P <0.002).>
Sources:
Vascular Disease in Mice With a Dysfunctional Circadian Clock
Ciprian B. Anea, MD; Maoxiang Zhang, PhD; David W. Stepp, PhD; G. Bryan Simkins, BS; Guy Reed, MD; David J. Fulton, PhD; R. Daniel Rudic, PhD
From the Department of Pharmacology and Toxicology (C.B.A., M.Z., G.B.S., D.J.F., R.D.R.), Department of Physiology (D.W.S.), Vascular Biology Center (D.W.S., D.J.F.), and Cardiology Division, Department of Medicine (G.R.), Medical College of Georgia, Augusta.
Circulation. 2009;119:1510-1517
Published online before print March 9, 2009, doi: 10.1161/CIRCULATIONAHA.108.827477
Adverse metabolic and cardiovascular consequences of circadian misalignment
Frank A. J. L. Scheer, Michael F. Hilton, Christos S. Mantzoros, and Steven A Shea
Division of Sleep Medicine, Brigham and Women's Hospital, Boston, MA 02115
Harvard Medical School, Harvard University, Boston, MA 02115; and
Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215
Published online before print March 2, 2009, doi: 10.1073/pnas.0808180106
PNAS March 17, 2009 vol. 106 no. 11 4453-4458
Friday, April 3, 2009
Indian polypill study
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60611-5/abstract
Indian scientists discover 'superpill' to combat heart disease Hindu - Mar 31, 2009
'Polypill' could reduce heart disease, stroke: Researchers Calgary Herald
5-in-1 pill passes first major test Times of India
Thursday, March 26, 2009
Nuts, Olive Oil, and Fish Oil
A recent trial randomized 772 subjects at high risk for CAD to a low-fat diet or a Mediterranean-style diet supplemented with either walnuts (30 g/day) or virgin olive oil (1 l/week). This trial found that after 3 months the Mediterranean diets supplemented with either nuts or olive oil produced clinically significant reductions in systolic blood pressure, fasting glucose, and inflammatory biomarkers compared with the low-fat diet.
Epidemiologic studies consistently indicate that consumption of nuts at least 5 times per week will reduce CAD and diabetes risks by 20% to 50%. Tree nuts are comprised predominantly of monounsaturated fats and are a rich source of antioxidants, fiber, phytosterols, magnesium, and folic acid, which might beneficially influence CV risk. Replacing refined carbohydrates with monounsaturated fats (using nuts and/or olive oil) will reduce post-prandial hyperglycemia and hypertriglyceridemia, increase high-density lipoprotein, and decrease oxidative stress . One practical way to accomplish this is to substitute nuts (all of which have very low glycemic indexes) for the sugary and starchy snack foods that are staples in the American diet.
Source:
Nonglycemic Effects of Incretins
In addition to their beneficial effects on blood glucose, particularly postprandial glucose, as well as body weight and pancreatic beta cell function, the glucagon-like peptide-1 (GLP-1) receptor agonists (Exenatide, Liraglutide) and dipeptidyl peptidase-4 (DPP-4) inhibitors (Sitagliptin, Vildagliptin) have other beneficial effects. These effects on blood pressure and blood lipids, although not making incretins suitable as primary therapy, may be important benefits to consider in selecting diabetes therapy, because patients with type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular disease.
Blood Pressure
GLP-1 receptor agonists and DPP-4 inhibitors produce modest reductions in systolic blood pressure and, in some cases, diastolic blood pressure. The importance of hypertension as a cardiovascular risk factor is well established. As concluded by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, each increment of 20/10 mm Hg above 115/75 mm Hg doubles the risk of cardiovascular disease.
Lipid Profile
Conclusion
The GLP-1 receptor agonists and DPP-4 inhibitors lower blood pressure and improve the lipid profile, which, although not appropriate as primary therapy, makes them especially valuable treatment options for patients with T2DM. These improvements may help to reduce the risk of cardiovascular events. Various approaches can be taken to initiate and modify GLP-1 receptor agonist and DPP-4 inhibitor therapy to improve efficacy and tolerability based on patient characteristics and concomitant therapies.
References
- Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2008. In press.
- Viswanathan P, Chaudhuri A, Bhatia R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444-450.
- Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8:419-428.
- Vilsboll T, Zdravkovic M, Le Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610.
- Colagiuri S, Frid A, Zdravkovic M, et al. The once-daily human GLP-1 analog liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Paper presented at: American Diabetes Association 68th Scientific Session; June 6-10, 2008; San Francisco, CA.
- Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592-598.
- Chobanian AV, Bakris GL, Black HR, et al; for the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
- Blonde L, Rosenstock J, Sesti G, et al. Liraglutide: superior glycemia control vs exenatide when added to metformin and/or SU in type 2 diabetes. Paper presented at: Canadian Diabetes Association/Canadian Society of Endocrinology and Metabolism Annual Meeting; October 15-18, 2008; Montreal, Quebec, Canada.
- Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171-180.
- Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; for the Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-1568.
- Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab. 2008;10:82-90.
- Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes. Diabetes Care. 2007;30:217-223.
- Grundy SM, Becker D, Clark LT, et al. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf. Accessed January 20, 2009.
- Daniel A. Nadeau, MD. Incretin Benefits Beyond Glycemic Control. From Primary Care Education Consortium, Medscape Internal Medicine. Posted 03/19/2009. Available at: http://www.medscape.com/viewarticle/588945?src=mp&spon=18&uac=82830HJ
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension
With the popularity of ACE inhibitors in mind, investigators conducted a systematic review of published studies to determine how effective the drugs actually are in reducing blood pressure. They also examined dose effectiveness, adverse effects, and the role of co-occurring conditions.
The Study Findings
Researchers looked for double-blind studies comparing ACE inhibitors and placebo. All included studies were at least 3 weeks in duration and measured blood pressure as an endpoint at 3-12 weeks. Studies that featured a response-dependent titration of medications were included in the review. Only research that focused on patients with a blood pressure above 140/90 mm Hg was reviewed.
The review included 92 trials with a total of 12,954 participants (mean age, 54 years). Mean baseline blood pressure was 157/101 mm Hg and mean pulse pressure was 56 mm Hg. The majority (75%) of included studies was industry-sponsored, and 82% of the trials examined fixed-dose ACE inhibitors. The duration of trials was generally short, which limited data with regard to adverse events and study withdrawals.
The main potential source of bias in the research was a lack of information with regard to how the studies were blinded. In addition, the reviewers suggested that the researchers could have preferentially selected patients more likely to respond to ACE inhibitors. This selection bias could make ACE inhibitors appear more effective than they truly are.
The studies covered 14 ACE inhibitors. The degree of homogeneity with regard to their efficacy in reducing blood pressure was remarkable. No one medication appeared superior to others.
Overall, ACE inhibitors had a modest collective effect in reducing blood pressure. The mean reduction in systolic blood pressure ranged between 6 mm Hg and 9 mm Hg, and the mean reduction in diastolic blood pressure was 4-5 mm Hg. Less data were available with regard to the blood pressure effects of ACE inhibitors at 1-12 hours after dosing, but the average decrease in blood pressure with ACE inhibitors around their peak concentration was greater than their average efficacy (11.4/6.4 mm Hg).
Dose Effectiveness
The study provided some important information about the relationship between the dose of ACE inhibitors and their effect on blood pressure. Doses lower than the manufacturers' maximum recommended dosage had the same blood pressure-lowering effect as the maximum dose. For example, doses of one eighth to one quarter of the maximum achieved the blood pressure-lowering effect of the maximum dose in 60% to 70% of cases. Half of the maximum dose achieved it 90% of the time. There was no blood pressure-lowering effect at or below one sixteenth of the maximum suggested dose. These data suggest that use of the maximum dosage of ACE inhibitors to achieve greater blood pressure control is usually unnecessary.
The research also identified dosing information for individual ACE inhibitors and suggested that the manufacturers' recommended starting doses of benazepril, moexipril, and ramipril are higher than the minimum dose needed to reduce blood pressure. Conversely, captopril did not appear effective in reducing blood pressure at the manufacturers' recommended starting dose. Most of the maximum blood pressure-lowering effect of lisinopril was achieved at only one eighth of the recommended maximum dose.
ACE inhibitor dosing was also one of the biggest deficits in the current review. It was clear to the review authors that not all data in regard to the efficacy of different doses of ACE inhibitors were published. Instead, the data were supplied to regulators privately to determine the appropriate dosing range of ACE inhibitors.
Only half of trials provided data in regard to the rate of withdrawal due to adverse events. Collectively, there was no difference between ACE inhibitors and placebo in this critical outcome. ACE inhibitors did not significantly affect patients' heart rate.
Addressing Other Health Issues
Physicians might choose ACE inhibitors to treat hypertension for other possible health benefits associated with these medications, especially the potential to prevent type 2 diabetes. ACE inhibitors can have a positive effect on glucose metabolism through multiple mechanisms, and previous research suggested that they could prevent incident diabetes compared with other antihypertensive medications. Specifically, the Captopril Prevention Project demonstrated a 14% relative reduction in this outcome among participants receiving captopril vs a diuretic or beta-blocker. This benefit, associated with captopril, was evident regardless of the baseline risk for diabetes, although the incidence of diabetes was not a primary outcome of the study.
The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial directly examined the effect of ramipril vs placebo on the incidence of diabetes. This study examined patients with impaired fasting glucose levels or reduced insulin sensitivity but no history of cardiovascular disease. After a median of 3 years of treatment, ramipril was not associated with a significantly lower incidence of diabetes compared with placebo. Median fasting plasma glucose levels were also similar at the end of the trial. However, ramipril was associated with a higher rate of return to normoglycemia.
Physicians might also consider using ACE inhibitors for hypertension in order to prevent incident heart failure. However, although ACE inhibitors are associated with numerous positive outcomes, including reduced mortality, among patients with known heart failure, little evidence exists that they provide special protection against new heart failure. In a study of quinapril and placebo initiated shortly after myocardial infarction, there was no difference between treatment groups in a composite outcome of cardiovascular death and significant cardiovascular events. Specifically, no difference was found in the risk for heart failure among those patients at high cardiovascular risk. Similarly, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Hearth Attack Trial (ALLHAT), the incidence of heart failure was similar among patients receiving lisinopril and chlorthalidone.
Commentary
Although ACE inhibitors may not provide special protection against diabetes or heart failure among patients with hypertension, physicians should still consider these medications when managing hypertension. In fact, the nature of hypertension management dictates that they have to because most patients require more than 1 medication initially. In a recent study of men receiving care at a Veteran Affairs hospital, 60.4% of subjects with hypertension and significant cardiovascular risk were receiving multiple antihypertensive medications. Nevertheless, only 28% of these same patients had reached their goal blood pressure levels, indicating that they needed titration of their medications, if not the addition of other antihypertensive drugs.
Authors' conclusions
Clinical Pearls
- In the current review, ACE inhibitors were associated with an average reduction in systolic blood pressure between 6 mm Hg and 9 mm Hg and in diastolic blood pressure of 4-5 mm Hg;
- ACE inhibitors achieved most of their power in reducing blood pressure at half of the maximum recommended dose, or less;
- ARBs provide similar reductions in blood pressure compared with ACE inhibitors; and
- There is no strong evidence that ACE inhibitors can prevent incident diabetes mellitus or heart failure.
Thursday, March 19, 2009
3000 Steps In 30 Minutes for a Meaningful Exercise Program
They have determined that a rate of at least 100 steps per minute achieves moderate intensity activity. According to them, a simple pedometer-based recommendation of 3000 steps in 30 minutes can get people started on a meaningful exercise program.
The researchers monitored 58 woman and 39 men for oxygen uptake while walking on a treadmill. The subjects completed 46-minute sessions at different treadmill speeds between 65 and 110 meters per minute. All subjects wore pedometers, and their heart rates were recorded.
The research team used 3 METs, or metabolic equivalents, as the minimum level of oxygen demand which approximates moderate exercise, to monitor participants in order to determine whether they had reached the moderate-exercise level at a given treadmill speed. From these data, the researchers found that for men, step counts associated with walking at 3 METs were between 92 and 102 steps per minute. For women, according to them, the range was between 91 and 115 steps per minute.
The study been published in the American Journal of Preventive Medicine.
Source-ANI
ARU/SK
Thursday, March 12, 2009
Final Results of ACCOMPLISH Show Benefit of Fixed-Dose Combination as Initial Therapy
The main results of the ACCOMPLISH trial, which demonstrated the superiority of a combination of initiating antihypertensive therapy with an ACE inhibitor plus a calcium channel blocker (CCB) over initiating with a thiazide-type diuretic, have been published in The New England Journal of Medicine, approximately 9 months after preliminary findings were presented at the annual Scientific Sessions of the American College of Cardiology. These results challenge current US hypertension guidelines, which recommend inclusion of a diuretic in first-line combination therapy.
Between 2003 and 2005, the international ACCOMPLISH trial randomized 11,506 patients with hypertension (mean age 68.4 years) who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide (HCTZ) as single capsule formulations. The only other antihypertensive medications permitted were beta-blockers, alpha-blockers, clonidine, and spironolactone. The trial was terminated early, after a mean follow-up of 36 months, when an interim analysis showed overwhelming efficacy in favor of the benazepril-amlodipine combination. Mean blood pressures after dose adjustment were 131.6/73.3 mm Hg in the benazepril-amlodipine group and 132.5/74.4 mm Hg in the benazepril-HCTZ group. Rates of blood pressure control (<>
The primary endpoint was the composite of death from cardiovascular causes, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization. There were 552 primary-outcome events in the benazepril-amlodipine group (9.6%) compared with 679 in the benazepril-HCTZ (11.8%), representing an absolute risk reduction with benazepril-amlodipine therapy of 2.2% and a relative risk reduction of 19.6%. For the secondary endpoint of death from cardiovascular causes, nonfatal MI, and nonfatal stroke, the hazard ratio was 0.79. Rates of adverse events were similar in the 2 treatment groups and consistent with those observed from clinical experience with the drugs.
In a press release issued by the University of Michigan Health System, Ann Arbor, lead investigator Kenneth Jamerson, MD, said, "This robust study showed us that switching patients to a single-pill combination meant that twice as many patients got to their blood pressure goal, regardless of previous therapy. The significant reduction in cardiovascular events we observed in patients will, I hope, show physicians that earlier use of a combination medication, especially with amlodipine, may be in the best interest of patients."
caution against combining the 2 classes of RAS inhibitors
The updated recommendation is based on the results of the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), an international study supported by Boehringer Ingelheim, the Heart and Stroke Foundation of Ontario, and the Canadian Institutes of Health Research. The main results of ONTARGET, published in 2008,[9] showed that in 25,620 patients with vascular disease or type 2 diabetes, the combination therapy had a greater blood pressure-lowering effect than either telmisartan or ramipril alone, but it did not produce any additional benefit in terms of patient outcomes, and it was associated with more side effects, such as hyperkalemia, hypotension, and renal impairment. The guidelines also note that in patients with stage 3 chronic kidney disease (glomerular filtration rate > 30 mL/min) the ACE inhibitor plus ARB combination reduced urine protein but did not reduce cardiovascular outcomes, and it worsened renal outcomes, including the need for acute dialysis compared with the ACE inhibitor alone.
The only data to support improved patient outcomes with the combination of an ACE inhibitor plus an ARB are in people with heart failure, where, the guidelines note, the combination reduces recurrent hospitalization. Hence, the guidelines advise that the use of combination of ACE inhibitor with an ARB therapy should only be considered in selected and closely monitored people with advanced heart failure or proteinuric nephropathy. They advise that for people already on the combination and stable, physicians should consider that prescribing 1 of the 2 drug classes alone will reduce cardiovascular events to the same extent and that other therapeutic regimens have the potential to reduce cardiovascular events and blood pressure to a greater degree. Trials are ongoing of a combination of an ACE inhibitor with an ARB in people with chronic kidney disease and diabetes.
Thursday, February 19, 2009
Fatty acids profile of edible oils and fats in our diet in India
Tuesday, February 3, 2009
Impact of JUPITER
In the newest analysis, investigators used data from the National Health and Nutrition Examination Survey (NHANES 1999–2004) to estimate the size of the population that would be affected by the JUPITER findings as well as to describe the population for whom statin therapy might now be indicated.
The group identified 2322 individuals with complete data to determine statin eligibility. More than half, 57.9%, and representing more than 33 million US adults, had a National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) indication for statin therapy. Of these, only 42% were currently taking a statin.
Of the remaining 976 subjects, 13.9%, representing eight million US adults, met the strict JUPITER criteria of hs-CRP >2.0 mg/L and LDL cholesterol <130 mg/dL. Another 5.3%, representing three million adults, had an extended JUPITER indication--elevated CRP and LDL-cholesterol levels between 130 and 160 mg/dL--for statin therapy.
"In the middle-aged and older population, there are already a huge number of people--58%, or 33 million Americans--who meet the current recommendations to take a statin," Spatz told heartwire. "If we are to adopt JUPITER to clinical practice, this would add an additional 11 million people, or another 20% of the population."
As noted, the secondary analysis of the NHANES data revealed that less than half of patients currently meeting the existing recommendations for statin therapy are receiving the lipid-lowering drugs.
In looking at patient characteristics, the researchers noted that compared with individuals in whom statins would not be indicated, the JUPITER patients were more likely to be female and older. There were also more likely to be obese, hypertensive, and have the metabolic syndrome. They also noted that many of JUPITER patients shared similar characteristics, including sociodemographic factors, abdominal obesity, and hypertension, as those who qualified for statin therapy based on the NCEP ATP III guidelines.
An analysis of cardiovascular risk scores showed that Framingham risk score (FRS) was higher in patients who met the NCEP ATP III guidelines for statin therapy but similar in the JUPITER patients and patients without an indication for statin therapy. The Reynolds risk score, which includes additional risk factors beyond the FRS, including hs-CRP, was able to differentiate risk between those who met the criteria for statins based on JUPITER patients and those without an indication for the drugs, said Spatz
Sunday, December 28, 2008
rosuvastatin reduces the risk of cardiovascular events by 54% in people who do not have high cholesterol level after 2 years
The original research article and an editorial was recently published in NEJM. There are two important issues regarding the results of this trial
1. Long term safety of rosuvastatin is not yet established. If we are going to start rosuvastatin for a low risk subject without any clinical disease for primary prevention, he will be taking it for a long period say 20 years. In such case without long term safety being established, it should not be advised.
2. Secondly the patency of rosuvastatin is now held by Astra Zeneca and the drug is very costly now. If this protective effect is a class effect then the cheaper statins which have become generic can be substituted.
Tuesday, December 16, 2008
Aggressively lowering of blood sugar lead to more deaths
Source
Free Books, powerpoint presentations, teaching tools and resources and drug information
-
Microbiology Lecture Notes - SET 4 - Powerpoint links collected from the website of : Lauren Brandon, Ph.D , Associate Professor of Microbiology Introduction to Microbiology Microbial Cell...9 years ago
-
Is Vitapulse a Scam? - The heart is a vital organ of the body and it plays major roles in its general functioning. Proper healthcare should be taken to ensure the heart functio...10 years ago
-
Atypical Thyrotoxicosis Relapse after Carbimazole Discontinuation: A Case Report with Pharmacological View - authors: Sharique Ahmad, Saeeda Wasim, Mohammed Tariq Salman, Mohammed Aqwam Siddiqui, Nahid Shabnam, Pragya Khanna A 15-year-old girl who presented with p...11 years ago
-
RSS and Libraries - RSS and Its Use In Libraries View more presentations from Sukhdev Singh. (tags: rss libraries)17 years ago
-
For Computer-lOvErS - *Antivirus SofTwArEs* Norton 360 (Up To 12 Years Key) Norton AntiVirus 2008 AVG Antivirus Panda.Antivirus NOD32 Antivirus Kingsoft Antivirus Kaspersky...17 years ago
-
Contemporary Targeted Therapies in Rheumatology - Publisher: Informa Healthcare Number Of Pages: 636 Publication Date: 2007-10-24 ISBN-10 / ASIN: 1841844845 ISBN-13 / EAN: 9781841844848 Binding: Hardcover ...18 years ago
-
-
-
-
-
-
-